CAS: 20830-75-5; Digoxin

该化合物是来自狐球厂叶叶叶的心球,主要用于治疗各种心脏状况,特别是性纤维化和心脏衰竭.它的作用是抑制ATPase泵钠-钾,导致细胞内钙浓度增加,从而增加心脏萎缩性.Digoxin的特征是其相对狭窄的治疗窗口,这意味着有效剂量和有毒剂量之间的差别很小,需要仔细监测病人血清水平.它通常通过口服或静脉注射进行,并因其潜在的副作用而为人所知,其中可包括胃肠扰动,视觉变化和心律不齐.该物质有C41H64O14的分子分子配方,分子重量约为780.94克/摩尔.Digoxin's药理学受诸如肾功能和与其他药物相互作用等因素的影响,使个人化的剂量成为安全和有效使用的必要条件.

结构式图片

欧盟法规

ECHA物质ECHA物质C&L通报REACH预注册

上下游产品

beta-Acetyldigoxin 3'''-acetyldigoxin digitoxin lanatoside CDigoxigenin mono-digitoside Digoxigenin bisdigitoxide digoxigenin 3β,14-Dihydroxy-12-oxo-5β,14β-card-20(22)-enolid

合成工艺路线路线简述

    📜毛花苷c置于氢氧化钾,Enzyme-Substance From Digitalis Lanata体系中,化学反应生成地高辛
    参考文献:乙酰数字毒素,乙酰基毒素和乙酰基地高辛(5. Mitteilungüberherzglucoside)
    标题:乙酰数字毒素,乙酰基毒素和乙酰基地高辛(5. Mitteilungüberherzglucoside)
    摘要:
    Doi:10.1002/hlca.19340170169

    海关参考信息

    专利信息


    专利号:US-11059849-B2
    优先权日:2014-09-02
    标题 :Modified nucleotides for synthesis of nucleic acids, a kit containing such nucleotides and their use for the production of synthetic nucleic acid sequences or genes
    发明人:YBERT THOMAS; GARIEL SYLVAIN
    权利人:DNA SCRIPT
    摘要:A modified nucleotide, intended for the synthesis of long chain nucleic acids by enzymatic processes, comprising a “naturalâ€? nitrogenous base or a natural nitrogenous base analogue, a ribose or deoxyribose carbohydrate, and at least one phosphate group, characterized in that said nucleotide comprises at least one R group, termed the modifier group, carried by said nitrogenous base or analogue and/or by the oxygen in position 3′ of the ribose or deoxyribose molecule, making it possible to block the polymerization of said nucleotide and/or to allow the interaction of said nucleotide with another molecule, such as a protein, during the nucleic acid synthesis, R comprising at least one functional terminal group.

    专利号:US-2004038331-A1
    优先权日:2002-08-23
    标题:Solid phase synthesis of biomolecule conjugates
    发明人:REDDY M PARAMESWARA; FAROOQUI FIRDOUS; BRILLHART KURT L
    摘要:Processes for the solid state phase formation synthesis of biomolecule conjugates, particularly protein-oligonucleotide conjugates are shown. One of the protein or oligonucleotide is reversibly bound to a solid substrate phase. At least one portion of each of the protein and the oligonucleotide molecules is activated with complementary activation groups. The activated protein and the activated oligonucleotide are then reacted, in a buffered solution resulting in the formation of the desired conjugate which remains reversibly bound to the substrate. The nature of the buffered solution is then modified causing the conjugate to be released from the substrate solid phase.

    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-5763681-A
    优先权日:1989-09-06
    标 题 :Synthesis of stable, water-soluble chemiluminescent 1,2-dioxetanes and intermediates therefor
    发明人:EDWARDS BROOKS; JUO RHOU-RONG
    权利人:TROPIX INC
    摘要:A novel synthesis of compound having the formula: ##STR1## wherein T is a stabilizing spiro-linked polycycloalkylidene group, R 3 is a C 1 -C 20 alkyl, aralkyl or heteroatom containing group, Y is an aromatic fluorescent chromophore, and Z is a cleavable group which, when cleaved, induces decomposition of the dioxetane ring and emission of optically detectable light, is disclosed. A tertiary phosphorous acid alkyl ester of the formula: n n (R.sup.1 O).sub.3 P n n wherein R 1 is a lower alkyl group, is reacted with an aryl dialkyl acetal produced by reacting a corresponding aryl aldehyde with an alcohol of the formula: n n R.sup.3 OH n n wherein R 3 is as defined above, to produce a 1-alkoxy-1-aryl-methane phosphonate ester of the formula: ##STR2## reacting the phosphonate with base to produce a phosphonate-stabilized carbanion, reacting the carbanion with a ketone of the formula: ##STR3## wherein T is as defined above, to produce an enol ether of the formula: ##STR4## then oxygenating the double bond in the enol ether to give the corresponding 1,2-dioxetane compound.

    专利号:US-2002055185-A1
    优先权日:1997-08-07
    标 题 :Complex chemical compound, synthesis and various applications of said compound
    发明人:MINARD CLAIRE; CHAIX CAROLE; DELAIR THIERRY; MANDRAND BERNARD
    摘要:The invention concerns a complex chemical compound comprising a solid carrier and at least a conjugate consisting of an organic polymer and a plurality of priming biomers. The invention also concerns the synthesis of said chemical compound for biopolymer synthesis and the use of said complex chemical compound after synthesis as ligand for amplifying or detecting and/or capturing target molecules.

    专利号:US-9909168-B2
    优先权日:1998-11-09
    标 题 :Method of synthesizing nucleic acid
    发明人:NOTOMI TSUGUNORI; HASE TETSU
    权利人:NOTOMI TSUGUNORI; HASE TETSU; EIKEN CHEMICAL
    摘要:The present invention relates to an oligonucleotide having a novel structure and a method of synthesizing nucleic acid by using the same as a primer. This oligonucleotide is provided at the 5′-side of the primer with a nucleotide sequence substantially the same as a region synthesized with this primer as the origin of synthesis. The present invention realizes synthesis of nucleic acid based on an isothermal reaction with a simple constitution of reagents. Further, the present invention provides a method of synthesizing highly specific nucleic acid on the basis of this method of synthesizing nucleic acid.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Ehle M, Patel C, Giugliano RP. Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine. Crit Pathw Cardiol. 2011 Jun;10(2):93-8. doi: 10.1097/HPC.0b013e318221e7dd. Review. doi: 10.1038/nature09978. Epub 2011 Mar 27.
    4: Yukawa M, Yukawa E, Suematsu F, Takiguchi T, Ikeda H, Aki H, Mimemoto M. Determination of digoxin clearance in Japanese elderly patients for optimization of drug therapy: a population pharmacokinetics analysis using nonlinear mixed-effects modelling. Drugs Aging. 2011 Oct 1;28(10):831-41. doi: 10.2165/11594230-000000000-00000. Review. doi: 10.3265/Nefrologia.pre2011.Jul.10893. English, Spanish. doi: 10.4155/bio.09.14. Review. German.
    16: Omidfar K, Kia S, Kashanian S, Paknejad M, Besharatie A, Kashanian S, Larijani B. Colloidal nanogold-based immunochromatographic strip test for the detection of digoxin toxicity. Appl Biochem Biotechnol. 2010 Mar;160(3):843-55. doi: 10.1007/s12010-009-8535-x. Epub 2009 Feb 18.

    合成参考文献


    参考文献:10.1073/pnas.2005463117
    摘要:Abrams RPM, Yasgar A, Teramoto T, Lee MH, Dorjsuren D, Eastman RT, Malik N, Zakharov AV, Li W, Bachani M, Brimacombe K, Steiner JP, Hall MD, Balasubramanian A, Jadhav A, Padmanabhan R, Simeonov A, Nath A. Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. Proc Natl Acad Sci U S A. 2020 Dec 08;117(49):31365–75.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知